Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2026)

Spero Therapeutics (SPRO) has reported Income from Continuing Operations for 11 consecutive years, with -$9.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations fell 460.39% year-over-year to -$9.5 million; the trailing twelve-month figure through Jun 2026 stood at $5.8 million (up 110.81% YoY), and the FY2025 full-year result was $7.0 million, up 110.18% from the prior year.
• Income from Continuing Operations slipped to -$9.5 million in Q2 2026 per SPRO's latest filing, from -$7.2 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at $51.2 million in Q4 2023 and bottomed at -$30.1 million in Q1 2022.
• Historically, Income from Continuing Operations has averaged -$5.4 million across 5 years, with a median of -$11.8 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 247.36% in 2025, then slumped 460.39% in 2026.
• Over 5 years, Income from Continuing Operations stood at $26.8 million in 2022, then soared by 91.22% to $51.2 million in 2023, then tumbled by 139.67% to -$20.3 million in 2024, then surged by 247.36% to $29.9 million in 2025, then tumbled by 131.91% to -$9.5 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$9.5 million, -$7.2 million, and $29.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.